Idorsia shares track their worst day ever as talks for Tryvio rights stall
20/12/2024 08:26
** Shares in Idorsia IDIA.S drop 45%, on track for their
worst day ever, after the Swiss biopharma group said exclusive
talks for global rights to hypertension medication Tryvio had
stalled
** Analysts at RBC and Vontobel say addressing the lack of
liquidity is the priority for Idorsia going forward, as aside
from trying to complete the deal for Tryvio, also known as
aprocitentan, it is also restructuring and addressing
convertible bonds due in 2025 and 2028
** Vontobel says Idorsia needs to take these actions "rather
swiftly, as the current financial situation brings the company
just until the beginning of 2025"
(Reporting by Bernadette Hogg)
((bernadette.hogg@thomsonreuters.com))